G&E Herbal Biotechnology Co., Ltd. (TPEX:4911)
Taiwan · Delayed Price · Currency is TWD 29.05
-0.05 (-0.17%)
Aug 26, 2026, 1:30 PM CST
G&E Herbal Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 215.61 | 309.13 | 249.03 | 181.44 | 64.61 | 24.57 | |
Revenue Growth | -26.73% | 24.13% | 37.25% | 180.84% | 162.94% | -12.96% |
Cost of Revenue | 42.07 | 45.91 | 43.69 | 36.86 | 25.25 | 14.95 |
Gross Profit | 173.54 | 263.22 | 205.34 | 144.59 | 39.35 | 9.63 |
Selling, General & Admin | 64.92 | 76.03 | 50.36 | 39.3 | 19.48 | 16.65 |
Research & Development | 25.71 | 34.89 | 35.34 | 24.6 | 14.39 | 12.54 |
Operating Expenses | 90.62 | 110.92 | 85.7 | 63.9 | 33.87 | 29.19 |
Operating Income | 82.92 | 152.3 | 119.65 | 80.68 | 5.49 | -19.56 |
Interest Expense | -0.02 | -0.03 | -0.04 | -0 | - | - |
Interest & Investment Income | 6.46 | 6.55 | 4.48 | 4.4 | 0.6 | 0.52 |
Currency Exchange Gain (Loss) | -0.47 | -0.47 | 0.03 | 0.01 | 1.06 | -0.39 |
Other Non Operating Income (Expenses) | 0.41 | 0.07 | 0.63 | 0.31 | 0.08 | 0 |
EBT Excluding Unusual Items | 89.29 | 158.43 | 124.74 | 85.4 | 7.23 | -19.43 |
Gain (Loss) on Sale of Assets | -0.03 | -0.03 | -0.01 | -0.01 | -0 | -0.02 |
Legal Settlements | - | - | - | 5.12 | - | - |
Other Unusual Items | - | - | - | - | - | 1.22 |
Pretax Income | 89.26 | 158.39 | 124.73 | 90.5 | 7.23 | -18.22 |
Income Tax Expense | 3.01 | 19.2 | 22.67 | 18.1 | -0.15 | 1.66 |
Net Income | 86.25 | 139.2 | 102.06 | 72.4 | 7.38 | -19.88 |
Net Income to Common | 86.25 | 139.2 | 102.06 | 72.4 | 7.38 | -19.88 |
Net Income Growth | -35.93% | 36.38% | 40.97% | 880.90% | - | - |
Shares Outstanding (Basic) | 69 | 69 | 69 | 69 | 69 | 69 |
Shares Outstanding (Diluted) | 69 | 69 | 69 | 69 | 69 | 69 |
Shares Change | 0.17% | 0.08% | 0.06% | 0.08% | - | - |
EPS (Basic) | 1.25 | 2.02 | 1.48 | 1.05 | 0.11 | -0.29 |
EPS (Diluted) | 1.25 | 2.02 | 1.48 | 1.05 | 0.11 | -0.29 |
EPS Growth | -36.11% | 36.25% | 40.82% | 901.00% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 18.11 | 66.98 | 128.76 | 107.96 | 97.01 | -10.96 |
Free Cash Flow Per Share | 0.26 | 0.97 | 1.87 | 1.57 | 1.41 | -0.16 |
Dividend Per Share | 1.080 | 1.080 | 0.704 | 0.461 | - | - |
Dividend Growth | 66.39% | 53.43% | 52.65% | - | - | - |
Gross Margin | 80.49% | 85.15% | 82.46% | 79.69% | 60.91% | 39.17% |
Operating Margin | 38.46% | 49.27% | 48.04% | 44.47% | 8.49% | -79.61% |
Profit Margin | 40.00% | 45.03% | 40.98% | 39.90% | 11.42% | -80.92% |
Free Cash Flow Margin | 8.40% | 21.67% | 51.70% | 59.50% | 150.15% | -44.61% |
EBITDA | 92.72 | 162.03 | 129.24 | 89.9 | 14.89 | -10.23 |
EBITDA Margin | 43.00% | 52.41% | 51.90% | 49.55% | 23.04% | -41.62% |
D&A For EBITDA | 9.8 | 9.73 | 9.59 | 9.22 | 9.4 | 9.33 |
EBIT | 82.92 | 152.3 | 119.65 | 80.68 | 5.49 | -19.56 |
EBIT Margin | 38.46% | 49.27% | 48.04% | 44.47% | 8.49% | -79.61% |
Effective Tax Rate | 3.37% | 12.12% | 18.17% | 20.00% | - | - |